Results 1,321-1,340 of 2,022 for speaker:John Brassil
- Written Answers — Department of Health: Home Care Packages Provision (13 Jul 2017)
John Brassil: 510. To ask the Minister for Health the status of the home care package application for a person (details supplied); and if he will make a statement on the matter. [33648/17]
- Written Answers — Department of Health: Drugs Payment Scheme (13 Jul 2017)
John Brassil: 511. To ask the Minister for Health the status of an application for a drugs payment scheme card for a person (details supplied); and if he will make a statement on the matter. [33649/17]
- Written Answers — Department of Health: Hospitals Capital Programme (13 Jul 2017)
John Brassil: 512. To ask the Minister for Health if the capital submission that has been finalised by University Hospital Kerry in respect of a dedicated obstetric theatre is sanctioned for approval and escalation to the acute hospitals division as a matter of urgency in order for consideration of funding by the national estates; and if he will make a statement on the matter. [33653/17]
- Written Answers — Department of Health: Medicinal Products Prices (13 Jul 2017)
John Brassil: 616. To ask the Minister for Health the number of medicines that have had their price reduced as of 1 July 2017 with reference to the framework agreement on the supply and pricing of medicines; the details of each medicine; and the extent of the price cut. [33879/17]
- Written Answers — Department of Health: Primary Care Reimbursement Service Payments (13 Jul 2017)
John Brassil: 617. To ask the Minister for Health if online PCRS processing has now been extended to dentists and clinical dental technicians. [33880/17]
- Written Answers — Department of Health: Medical Card Administration (13 Jul 2017)
John Brassil: 618. To ask the Minister for Health when the web based paperless medical card application process to reduce the number of paper based applications will be implemented. [33881/17]
- Written Answers — Department of Health: Primary Care Strategy (13 Jul 2017)
John Brassil: 619. To ask the Minister for Health the progress which has been made on considering further recommendations of the clinical advisory group, including conclusions on the assessment of the burden of disease as agreed for implementation by the HSE and his Department. [33882/17]
- Written Answers — Department of Health: Primary Care Strategy (13 Jul 2017)
John Brassil: 620. To ask the Minister for Health if the HSE has developed a burden of the illness assessment tool. [33883/17]
- Written Answers — Department of Health: Medicinal Products Regulation (13 Jul 2017)
John Brassil: 621. To ask the Minister for Health the additional resources which have been provided to ensure that the assessment process for new medicines is implemented effectively. [33884/17]
- Written Answers — Department of Health: General Practitioner Training (13 Jul 2017)
John Brassil: 622. To ask the Minister for Health if new arrangements for management of GP training involving the Irish College of General Practitioners have been finalised and implemented; and if he will make a statement on the matter. [33885/17]
- Written Answers — Department of Social Protection: Social Welfare Benefits (13 Jul 2017)
John Brassil: 1189. To ask the Minister for Social Protection her plans to address the current qualifying criteria for the widowed surviving civil partner parent grant; her further plans to extend this grant to children of long-term cohabiting parents; and if she will make a statement on the matter. [33845/17]
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: I welcome the witnesses and thank them for attending the meeting. I have some general questions. We have heard that approximately 14% of the health budget is spent on drugs. Could we get a breakdown of how much of that 14% is spent on high-tech or orphan drugs in order that we can make comparisons? Could Professor Barry tell us where we lie in comparison with other EU countries on drug...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: Outside, did Professor Barry say that his team had four people?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: Sorry.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: Have the nine extra members been approved?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: The NCPE is working at 50% of capacity.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: Actually, I will rephrase that. The NCPE needs 100% more staff to do the job required of it.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: What of a review of a drug that does not pass assessment?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: Mr. Hennessy or Mr. Flanagan might say when there will be a further decision on Respreeza. A number of patients have been operating on a month-to-month basis, which is unsatisfactory, as the witnesses can imagine.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
John Brassil: My question is along the same lines. In any walk of life, organisation or process review a decision is reached based on best knowledge and information, which is very much respected. Is there a review mechanism with regard to the final decision of the witnesses, whereby somebody else can take a clean look at it? Two outcomes can differ. I am not saying the witnesses' analysis would be...